Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The prospective, single-arm phase II Keystone-001 trial evaluated three cycles of neoadjuvant pembrolizumab plus paclitaxel and cisplatin, specifically for resectable stage III ESCC
The target hematocrit was 28% to 33% throughout the study, and a protocol for erythropoietin dosing was established
DNA molecules are made up of multiple chromosomes which carry invaluable information in our body
To achieve the best results, application protocols typically recommend use on clean skin to enhance absorption and efficacy
US$ 27.51
US$ 26.42
US$ 23.71
-agonists-market-key-insight.png)
US$ 25.01
